All News

Foluso A. Fakorede, MD, sketched a disturbing picture of recognition and management of PAD in the US, highlighting stark racial and ethnic disparities and making an urgent call to action.

The highest CRC mortality rates occur at the “intersection of race, place, and class," Rachel Issaka, MD, MAS, told internal medicine clinicians at the annual ACP meeting.

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

ACP 2025: Kim Sandler, MD, discussed the latest screening guidelines, real-world challenges in implementation, and the essential role of shared decision-making.

Dagogo-Jack reviewed alarming data on the damage prediabetes can inflict even decades before a diabetes diagnosis and offered guidance to the internal medicine audience.

Your daily dose of the clinical news you may have missed.

William Lewis, MD, discussed the importance of photo-documentation, referral indicators, efficacy of various treatments, and other topics.

ACP 2025. A quick look at 2 topics in dermatology rounded out a Multiple Small Feedings of the Mind session at the 2025 American College of Physicians annual meeting.

ACP 2025. Ruth Etzioni, PhD, discussed evidence-based approaches to screening for patients at average risk, start and stop criteria, MRI for follow-up screening, and other topics.

ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.

ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Highlights from AAD 2025: Experts share updates on systemic therapy for atopic dermatitis, pediatric rashes, and contact dermatitis for PCPs.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.